My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 10 703 / DOI: 10.3332/ecancer.2016.703

Conference Report

Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7–10 October 2016

After years of trials, Programmed Death Ligand and Receptor targeting finally debuts as a firstline therapy in combination and as a single agent regimen at the 2016 European Society of Medical Oncology (ESMO) Congress. The meeting brought together 20,522 attendees, from over 120 countries, to share updates and novel technologies from a wide swathe of oncology research. This year’s theme, From Disease Treatment to Patient Care, was matched by abstract presentations starting from inception of care regimens to new standards of care in high-risk patient subgroups, to wellbeing of care providers, and finally the funding obstacles at each continental level.

Keywords: ESMO, checkpoint immunotherapy, lung cancer, bladder cancer, ovarian cancer, breast cancer, CDK, fulvestrant, PD-1, PD-L1, PARP inhibition, urothelial cancer

Loading Article Metrics ... Please wait

Related videos

Related articles

Research: Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy

Abstract | Full Article | PDF Published: 15 Aug 2017 / DOI: 10.3332/ecancer.2017.759

Review: Hypoxia-inducible tumour-specific promoters as a dual-targeting transcriptional regulation system for cancer gene therapy

Abstract | Full Article | PDF Published: 06 Jul 2017 / DOI: 10.3332/ecancer.2017.751

Research: Brain imaging before primary lung cancer resection: a controversial topic

Abstract | Full Article | PDF Published: 20 Jun 2017 / DOI: 10.3332/ecancer.2017.749

Special Issue: The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches

Abstract | Full Article | PDF Published: 08 Jun 2017 / DOI: 10.3332/ecancer.2017.746

Special Issue: Radioguided localisation of non-palpable lesions of the breast in Costa Rica: Review of results of our first 800 patients in private practice

Abstract | Full Article | PDF | Spanish Published: 08 Jun 2017 / DOI: 10.3332/ecancer.2017.745



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence